Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
SIMPLE SUMMARY: Only 10–20% of patients with newly diagnosed resectable pancreatic adenocarcinoma have potentially resectable disease. Upfront surgery is the gold standard, but it is rarely curative. After surgical extirpation of tumors, up to 80% of patients will develop cancer recurrence, and the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469083/ https://www.ncbi.nlm.nih.gov/pubmed/34572951 http://dx.doi.org/10.3390/cancers13184724 |